Audeo Oncology, which is developing a combination therapy in Phase 3 trial for metastatic colorectal cancer, postponed its IPO on Thursday, citing poor market conditions. The San Francisco, CA-based company was founded in 2006 and has yet to generate product revenue. Leerink Swann and Oppenheimer & Co. were set to be the joint bookrunners on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
